PHAXIAM Therapeutics S.A. (PHXM) Research

PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, which is currently undergoing Phase 3 clinical trials for advanced pancreatic cancer (second-line treatment) and Phase 2 studies for triple-negative breast cancer and relapsed acute lymphoblastic leukemia. Additionally, PHAXIAM is advancing a range of phage-based therapies designed to combat severe, drug-resistant bacteria. These pathogens are responsible for over two-thirds of nosocomial (hospital-acquired) infections that resist conventional treatments, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. Established in 2004 and headquartered in Lyon, France, the company was previously known as ERYTECH Pharma S.A. before adopting its current name, PHAXIAM Therapeutics S.A., in June 2023.

Market snapshot

Symbol
PHXM
Price
$3.10
Day change
-5.20%
Market cap
$1.0M
P/E ratio
-0.02x
52-week range
2.5-13.0
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • AlphaTON Capital Corp. (ATON)
  • COSCIENS Biopharma Inc. (CSCI)
  • Dominari Holdings Inc. (DOMH)
  • Elevation Oncology, Inc. (ELEV)
  • Kineta, Inc. (KA)
  • MEI Pharma, Inc. (MEIP)
  • MetaVia Inc. (MTVA)
  • Nymox Pharmaceutical Corporation (NYMXF)

Open PHAXIAM Therapeutics S.A. (PHXM) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.